• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Antti Luiro

Head of Nordic ER Development, Analyst

Antti Luiro portrait

Coverage

LeadDeskNightingale HealthAiforia TechnologiesQt Group

Latest content

ShowingAll content types

Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB

Analyst Comment 16.06.2026 klo 09.16 by Antti Siltanen, Antti Luiro
Aiforia Technologies

Nightingale: We factored the project delay into our estimates

Research 12.06.2026 klo 10.20 by Antti Siltanen, Antti Luiro
Nightingale Health

M&A activity in digital pathology is increasing

Analyst Comment 15.05.2026 klo 09.45 by Antti Siltanen, Antti Luiro
Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account

Qt Group Q4'25: Sentiment is glum and expectations are moderate

Research 27.02.2026 klo 13.28 by Antti Luiro, Atte Riikola
Qt Group

Canatu's expanding DENSO cooperation paves the way into the automotive segment's largest market pocket

Analyst Comment 05.01.2026 klo 09.08 by Antti Luiro
Canatu

Tecnotree agreed on an extension for the payment and conversion of unpaid convertible bonds

Analyst Comment 02.01.2026 klo 09.18 by Antti Luiro
Tecnotree

Nexstim's exclusivity agreement with Sinaptica proceeds with revised payment structure

Analyst Comment 29.12.2025 klo 10.12 by Antti Luiro
Nexstim

Aiforia changes CFO

Analyst Comment 23.12.2025 klo 09.29 by Antti Luiro
Aiforia Technologies

Another welfare services country is piloting Nightingale's technology

Analyst Comment 18.12.2025 klo 19.54 by Antti Luiro, Antti Siltanen
Nightingale Health

New study on benefits of Nightingale blood test in identifying cardiovascular disease risk

Analyst Comment 18.12.2025 klo 10.14 by Antti Luiro, Antti Siltanen
Nightingale Health